FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3023267875> ?p ?o ?g. }

• W3023267875 endingPage "193" @default.
• W3023267875 startingPage "179" @default.
• W3023267875 abstract "ABSTRACT Prostate cancer (PC) is the commonest malignancy in men that causes significant morbidity and mortality. The incidence has quadrupled in the last three decades. This is predominantly due to its increased detection by excellent newer techniques like Prostate-specific antigen (PSA) evaluation, Transrectal ultrasonography (TRUS), Transrectal ultrasound-guided biopsy, Contrast enhanced ultra sound studies, Multiparametric (Mp) MRI (MpMRI) and Nuclear medicine. Its incidence shows a rise in India. With the availability of PSA and trans-rectal biopsy, nowadays the majority of prostate cancers (PC) are diagnosed at an asymptomatic early stage (T1). Most PC are adenocarcinomas while a small percentage are ductal carcinomas, mucinous carcinomas, signet ring cell carcinomas and small cell carcinomas. These variants have poor prognosis. The anatomy of prostate will help us to further understand the basis of TRUS studies. The whole prostate can be divided into Transition Zone (TZ),Central Zone (CZ) and Peripheral Zone (PZ). This zonal anatomy of prostate is vital to understand the PC, since PC is predominantly seen as follows: TZ – 20%; CZ – 10%; and PZ – 70%. PSA is an extremely valuable tool in the evaluation of PC. It is exclusively produced by the prostate and to a lesser extent by the seminal vesicles. It is present in all post-pubertal men and absent in women and men following radical prostatectomy. Though the PSA is a vital parameter to detect PC, it can also be elevated in: i) Benign prostrate hypertrophy; ii) Prostate inflammation; iii) Prostatic infarct; iv) Post-digital rectal examination; and v) Sexual activity. The normal value of PSA is 0-4 ng/mL. The two techniques that are available to assess PSA levels are polyclonal assay or monoclonal assay. The monoclonal assay is the most commonly used method the world over. The accepted PSA values are: <4ng/mL (normal); 4.0-10.00ng/mL (borderline) and >10 ng/mL (abnormal). Other than normal PSA values, there are other PSA parameters which are often useful in confirming the diagnosis of PC. These are: i) PSA density; ii) PSA velocity; iii) PSA doubling time; iv) Other markers like PCA3; and v) PC is associated with more protein bound PSA (less free PSA) than in BPH. Free PSA (FPSA) can enhance the specificity of the total PSA value for detection of the PC while reducing the number of unnecessary biopsies. Another new finding is that of levels of insulin like growth factor binding protein-2 (IGFBP-2) appear to be directly associated with the presence of PC. Prostate Biopsy: Ultrasound guided biopsy of the prostate still remains the most important technique for the diagnosis of PC. Different biopsies which are used for diagnosis of PC are: Saturation Biopsy, MRI Guided Biopsy and Fusion Biopsy. Use of Gleason Score for grading the PC: Gleason score is the grading system used to determine the aggressiveness of PC. This grading system can be used to choose appropriate treatment options. The tumour grades provide important information regarding how fast the cancer is likely to be growing and the likelihood of the cancer spreading to other parts of the body such as lymph nodes or bones. The pathologist assigns the grade of the tumour when he or she looks at the malignant cells under the microscope. The higher the Gleason grade, the more aggressive is the tumour. Histopathology: Variants of usual acinar adenocarcinoma defined in 2004 by the WHO, include atrophic, pseudohyperplastic, foamy, colloid, signet ring, etc. Recently, variants not included in the 2004 WHO classification are microcysticadeno carcinoma, prostatic intraepithelial neoplasia – adenocarcinoma, large cell neuro endocrine carcinoma and pleomorphic giant cell carcinoma. Other diagnostic modalities for PC are Colour Flow Imaging, Elastography, Contrast Enhanced Ultrasound (CEUS), MR Imaging of Prostate Malignancies. The MR Imaging consisting of the following: Prostate Imaging Reporting and Data System (PIRADS) refers to a structured reporting scheme for evaluating the prostate for PC. T1-weighted images are not helpful in differentiating different zones or detecting the lesion. However, invasion of neurovascular bundle, haemorrhage within the gland and loco-regional lymphadenopathy is better visualized on this sequence. DWI imaging plays an important role in determining PIRADS score, predominantly in peripheral zone neoplasm. It utilizes proton diffusion properties in water to produce image contrast. Thus prostate malignancy appears bright (hyperintense) on DWI with corresponding low values on ADC map (darkhypo intense).Of all functional MR imaging techniques, DW imaging is the most practical and simple in its use. Dynamic Contrast Scan is considered positive if a suspected lesion/ nodule on T2-W or DWI image reveals earlier than normal or more than normal enhancement (hyper enhancement), as routinely seen in lesions with malignant etiology. MR Spectroscopy reflects resonance frequencies that are unique for protons in different metabolites present at the sampled location. A change in the ratios of concentrations of these metabolites suggests abnormality within the tissue. Normal PZ has high concentration of citrate and polyamines and low concentration of choline and creatinine. A reversal of these, i.e. decrease in citrate peak due to altered metabolism and increase in choline and creatinine peaks in a suspected nodule on T2-W image may suggest malignancy. Recent studies reveal that MR spectroscopy is more specific and less sensitive that anatomic T2-W scan. Current Modalities of Prostate Cancer Treatments There are a wide variety of treatments available for the management of prostate cancer. Radical prostatectomy, external beam radiation and radioactive prostate seed implant are potential cures for the prostate cancer. Hormone therapy may force the cancer into a prolonged remission but does not provide a cure unless it is combined with other treatments. The most commonly used treatments include the following: • Watchful Waiting (Active surveillance) • Radical Prostatectomy (Robot assisted radical prostatectomy; Laparoscopic prostatectomy) • Radiation Therapy (External beam radiation; Radioactive prostate seed implants) • Hormone Therapy • Combination of Therapies • High Intensity Focused Ultrasound (HIFU) or Magnetic Resonance-guided Focussed Ultrasound Surgery (MRgFUS) • Others (Cryotherapy; Photodynamic therapy) • Metastatic Disease 1. Hormonal therapy (orchidectomy) 2. Anti androgens 3. Luteinizing Hormone-releasing Hormone (LHRH) Agonists (Leuprolide; Goserelin; Triptorelin; Histrelin) – monthly to annual depot injection S.C. implants Metastatic PC responds to androgen- ablation/deprivation therapy, which heralded the beginning of a new era PC therapy." @default.
• W3023267875 created "2020-05-13" @default.
• W3023267875 creator A5023592944 @default.
• W3023267875 date "2018-10-01" @default.
• W3023267875 modified "2023-09-25" @default.
• W3023267875 title "The Current Status of Prostate Cancer" @default.
• W3023267875 cites W1490266165 @default.
• W3023267875 cites W1502422706 @default.
• W3023267875 cites W1519436839 @default.
• W3023267875 cites W1567742721 @default.
• W3023267875 cites W1606164928 @default.
• W3023267875 cites W1671918366 @default.
• W3023267875 cites W1794768501 @default.
• W3023267875 cites W1827911007 @default.
• W3023267875 cites W1912479797 @default.
• W3023267875 cites W196212398 @default.
• W3023267875 cites W1964943167 @default.
• W3023267875 cites W1965717154 @default.
• W3023267875 cites W1972471919 @default.
• W3023267875 cites W1983225862 @default.
• W3023267875 cites W1989978030 @default.
• W3023267875 cites W2003607395 @default.
• W3023267875 cites W2004579918 @default.
• W3023267875 cites W2013338906 @default.
• W3023267875 cites W2015382161 @default.
• W3023267875 cites W2023325850 @default.
• W3023267875 cites W2026832536 @default.
• W3023267875 cites W2035397440 @default.
• W3023267875 cites W2040454516 @default.
• W3023267875 cites W2043421492 @default.
• W3023267875 cites W2049465221 @default.
• W3023267875 cites W2053277232 @default.
• W3023267875 cites W2055988043 @default.
• W3023267875 cites W2069574917 @default.
• W3023267875 cites W2084541894 @default.
• W3023267875 cites W2086328136 @default.
• W3023267875 cites W2116369771 @default.
• W3023267875 cites W2127757047 @default.
• W3023267875 cites W2128050497 @default.
• W3023267875 cites W2135951025 @default.
• W3023267875 cites W2137157171 @default.
• W3023267875 cites W2164942212 @default.
• W3023267875 cites W2177294379 @default.
• W3023267875 cites W2267247859 @default.
• W3023267875 cites W2288383567 @default.
• W3023267875 cites W2400668959 @default.
• W3023267875 cites W2401674736 @default.
• W3023267875 cites W2417371006 @default.
• W3023267875 cites W2510791923 @default.
• W3023267875 cites W2567606541 @default.
• W3023267875 cites W2591277748 @default.
• W3023267875 cites W2595216041 @default.
• W3023267875 cites W2783291377 @default.
• W3023267875 cites W2882079654 @default.
• W3023267875 cites W2889646458 @default.
• W3023267875 cites W2951195529 @default.
• W3023267875 cites W3025530333 @default.
• W3023267875 cites W46364339 @default.
• W3023267875 doi "https://doi.org/10.1055/s-0040-1712829" @default.
• W3023267875 hasPublicationYear "2018" @default.
• W3023267875 type Work @default.
• W3023267875 sameAs 3023267875 @default.
• W3023267875 citedByCount "0" @default.
• W3023267875 crossrefType "journal-article" @default.
• W3023267875 hasAuthorship W3023267875A5023592944 @default.
• W3023267875 hasBestOaLocation W30232678751 @default.
• W3023267875 hasConcept C119599485 @default.
• W3023267875 hasConcept C121608353 @default.
• W3023267875 hasConcept C126322002 @default.
• W3023267875 hasConcept C127413603 @default.
• W3023267875 hasConcept C143998085 @default.
• W3023267875 hasConcept C148043351 @default.
• W3023267875 hasConcept C2776235491 @default.
• W3023267875 hasConcept C2780192828 @default.
• W3023267875 hasConcept C71924100 @default.
• W3023267875 hasConceptScore W3023267875C119599485 @default.
• W3023267875 hasConceptScore W3023267875C121608353 @default.
• W3023267875 hasConceptScore W3023267875C126322002 @default.
• W3023267875 hasConceptScore W3023267875C127413603 @default.
• W3023267875 hasConceptScore W3023267875C143998085 @default.
• W3023267875 hasConceptScore W3023267875C148043351 @default.
• W3023267875 hasConceptScore W3023267875C2776235491 @default.
• W3023267875 hasConceptScore W3023267875C2780192828 @default.
• W3023267875 hasConceptScore W3023267875C71924100 @default.
• W3023267875 hasIssue "04" @default.
• W3023267875 hasLocation W30232678751 @default.
• W3023267875 hasOpenAccess W3023267875 @default.
• W3023267875 hasPrimaryLocation W30232678751 @default.
• W3023267875 hasRelatedWork W1980245127 @default.
• W3023267875 hasRelatedWork W2075763133 @default.
• W3023267875 hasRelatedWork W2088520467 @default.
• W3023267875 hasRelatedWork W2106003470 @default.
• W3023267875 hasRelatedWork W2124129753 @default.
• W3023267875 hasRelatedWork W2165919621 @default.
• W3023267875 hasRelatedWork W2400504790 @default.
• W3023267875 hasRelatedWork W2429027331 @default.
• W3023267875 hasRelatedWork W2433835599 @default.
• W3023267875 hasRelatedWork W4243514755 @default.

• next